GlassScriptPhysician profile
Bryce J Casteigne
NPI 1134681034
$2,584.27
in general payments reported to CMS, 2019-2025
28 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 79% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2024: $353 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.74 | 2024-2025 | |
| Pfizer INC. | $183.94 | 2024-2025 | |
| Biogen, INC. | $178.72 | 2024-2025 | Leqembi, Vumerity, Tysabri |
| Medtronic, INC. | $172.44 | 2025 | Protege Rx |
| Neurocrine Biosciences, INC. | $167.67 | 2024-2025 | Ingrezza |
| Ucb, INC. | $157.98 | 2024-2025 | Briviact, Nayzilam, Fintepla |
| Neurelis, INC. | $108.27 | 2024-2025 | Valtoco |
| Lundbeck LLC | $107.49 | 2024-2025 | Vyepti, Rexulti |
| Amgen INC. | $93.48 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $85.76 | 2025 | |
| Lilly USA, LLC | $77.88 | 2025 | Kisunla, Amyvid |
| Janssen Biotech, INC. | $76.81 | 2025 | |
| Acadia Pharmaceuticals INC | $73.45 | 2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $72.83 | 2024-2025 | Xeomin |
| Eisai INC. | $63.66 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.69 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Contego Medical, INC | $51.81 | 2025 | |
| Argenx US, INC. | $45.17 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $42.12 | 2025 | Ultomiris |
| Genentech USA, INC. | $41.29 | 2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $39.92 | 2024-2025 | Rexulti |
| Sk Life Science, INC. | $33.43 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.58 | 2025 | Hyqvia |
| Tg Therapeutics, INC. | $25.31 | 2025 | |
| Aucta Pharmaceuticals, INC. | $24.85 | 2025 | Motpoly Xr |
| Csl Behring | $20.56 | 2024 | Hizentra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.72 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $14.06 | 2025 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Casteigne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.